KP Tissue Inc. (KPT) (TSX: KPT) reports the Q2 2023 financial and
operational results of KPT and Kruger Products Inc. (Kruger
Products). Kruger Products is Canada's leading manufacturer of
quality tissue products for the Consumer market (Cashmere®, Purex®,
SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the
Away-From-Home (AFH) market and continues to grow in the U.S.
Consumer tissue business with the White Cloud® brand and premium
private label products. KPT currently holds a 13.3% interest in
Kruger Products.
Kruger Products Q2 2023 Business and Financial
Highlights
- Revenue was $466.3 million in Q2
2023 compared to $397.5 million in Q2 2022, an increase of $68.8
million or 17.3%.
- Adjusted EBITDA1 was $55.0 million in
Q2 2023, compared to $11.8 million in Q2 2022, an increase of
365.8%.
- Net income was $14.5 million in Q2
2023 compared to a net loss of $35.5 million in Q2 2022, an
increase of $50.0 million.
- Declared a quarterly dividend of
$0.18 per share to be paid on October 16, 2023.
“We are pleased that margin recovery, along with
improved sales volume and a better mix in our Consumer business,
generated strong Adjusted EBITDA of $55.0 million in the second
quarter of 2023,” stated KP Tissue’s Chief Executive Officer, Dino
Bianco. “Ongoing cost management initiatives, including
productivity gains and cost controls, also contributed to
increasing profitability. In addition, our Away-From-Home
segment delivered a fourth consecutive quarter of positive Adjusted
EBITDA to maintain its growth momentum. As a result, our financial
performance in the second quarter normalized versus a more
challenging market and operating environment in the same period
last year. On a sequential basis, revenue and Adjusted EBITDA
continued to improve, rising 3.4% and 10.2% in the quarter,
respectively.”
“Looking ahead to the second half of 2023, we
anticipate a more favourable landscape as input costs trend
downwards, TAD Sherbrooke and the Sherbrooke Expansion Project
continue to ramp up production capacity to meet customer demand,
and margins are restored to their pre-pandemic levels,” Mr. Bianco
added.
Outlook for Q3 2023For the
third quarter of 2023, as commodity and other input costs begin to
decline, we will focus on maintaining our margins while also
continuing to reinvest in the business to drive long-term value.
Accordingly, Adjusted EBITDA1 in Q3 2023 is expected to be in the
range of Q2 2023.
Kruger Products Q2 2023 Financial
ResultsRevenue was $466.3 million in Q2 2023 compared to
$397.5 million in Q2 2022, an increase of $68.8 million or 17.3%.
The increase in revenue was primarily due to the favourable impact
of selling price increases implemented across all segments and
regions during 2022, along with favourable sales mix and higher
sales volume in the Consumer business. Revenue was also favourably
impacted by foreign exchange fluctuations on U.S. dollar sales.
Cost of sales was $395.8 million in Q2 2023
compared to $372.5 million in Q2 2022, an increase of $23.3 million
or 6.2%. Higher sales volumes increased cost of sales, along with
the unfavourable impact of foreign exchange fluctuations on U.S.
dollar costs, partially offset by improvements in Memphis
operations. While the significant inflation experienced during 2022
has moderated in the second quarter of 2023, manufacturing input
costs remain higher than the year ago quarter. Freight rates were
lower compared to Q2 2022 as supply constraints and inflation
moderated, while warehousing costs increased as a result of
additional logistics network costs. As a percentage of revenue,
cost of sales was 84.9% in Q2 2023 compared to 93.7% in Q2
2022.
Selling, general and administrative (SG&A)
expenses were $40.6 million in Q2 2023 compared to $35.1 million in
Q2 2022, an increase of $5.5 million or 15.7%. The increase was
primarily due to higher personnel costs, foreign exchange losses
related to foreign denominated working capital and a loss on
disposal of fixed assets, partially offset by lower advertising
spend in the quarter. As a percentage of revenue, SG&A expenses
were 8.7% in Q2 2023 compared to 8.8% in Q2 2022.
Adjusted EBITDA1 was $55.0 million in Q2 2023
compared to $11.8 million in Q2 2022, an increase of $43.2 million
or 365.8%. The significant increase was primarily due to a
combination of factors: selling price increases in 2022, favourable
sales mix along with higher sales volumes, improvements in Memphis
operations and lower freight rates. These factors were partially
offset by inflation on input costs compared to Q2 2022, higher
warehousing and SG&A expenses and the unfavourable impact of
foreign exchange fluctuations.
Net income was $14.5 million in Q2 2023 compared
to a loss of $35.5 million in Q2 2022, an increase of $50.0
million. The increase was primarily due to higher Adjusted EBITDA1
and higher foreign exchange gains, partially offset by higher
income tax and depreciation expenses, higher interest expense and
other finance costs and a loss on sale of fixed assets.
1 Adjusted EBITDA is a non-GAAP financial
measure. Refer to the Non-GAAP Financial Measures section of this
news release for more information on these measures
Kruger Products Q2 2023
LiquidityTotal liquidity, representing cash and
availability under the revolving credit agreements, was $181.5
million as of June 30, 2023. In addition, $13.8 million of cash was
held by Kruger Products for the Sherbrooke Expansion Project.
KPT Q2 2023 Financial
ResultsKPT had net income of $2.0 million in Q2 2023.
Included in net income was $2.1 million representing KPT’s share of
Kruger Products’ net income, a dilution gain of $0.2 million and
depreciation expense of $0.3 million related to adjustments to
carrying amounts on acquisition.
Dividends on Common SharesThe
Board of Directors of KPT declared a quarterly dividend of $0.18
per share to be paid on October 16, 2023 to shareholders of record
at the close of business on October 2, 2023.
Additional InformationFor
additional information please refer to Management’s Discussion and
Analysis (MD&A) of KPT and Kruger Products for the second
quarter ended June 30, 2023 available on SEDAR
at www.sedar.com or our website
at www.kptissueinc.com.
Second Quarter Results Conference Call
InformationKPT will hold its second quarter conference
call on Thursday, August 10, 2023 at 8:30 a.m. Eastern Time.
Via telephone: 1-800-319-4610 or 604-638-5340
Via the internet at: www.kptissueinc.com
Presentation material referenced during the conference call will
be available at www.kptissueinc.com.
A rebroadcast of the conference call will be
available until midnight, August 17, 2023 by dialing 1-855-669-9658
or 604-674-8052 and entering passcode 0272.
The replay of the webcast will remain available on the website
until midnight, August 17, 2023.
About KP Tissue Inc. (KPT)KPT
was created to acquire, and its business is limited to holding, a
limited equity interest in Kruger Products, which is accounted for
as an investment on the equity basis. KPT currently holds a 13.3%
interest in Kruger Products. For more information visit
www.kptissueinc.com.
About Kruger ProductsKruger
Products is Canada's leading manufacturer of quality tissue
products for household, industrial and commercial use. Kruger
Products serves the Canadian consumer market with such well-known
brands as Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan®
and BonterraTM. In the U.S., Kruger Products manufactures the White
Cloud® brand, as well as many private label products. The
Away-From-Home division manufactures and distributes high-quality,
cost-effective product solutions to a wide range of commercial and
public entities. Kruger Products has approximately 2,700 employees
and operates nine FSC® COC-certified (FSC® C-104904) production
facilities in North America. For more information
visit www.krugerproducts.ca.
Non-GAAP Financial MeasuresThis
press release uses certain non-GAAP financial measures which Kruger
Products believes provide useful information to management of
Kruger Products and the readers of the financial information in
measuring the financial performance and financial condition of
Kruger Products. These measures do not have a standardized meaning
prescribed by GAAP and therefore may not be comparable to similarly
titled measures presented by other companies. An example of such a
measure is Adjusted EBITDA. Adjusted EBITDA is not a measurement of
operating performance computed in accordance with GAAP and should
not be considered as a substitute for operating income, net income
or cash flows from operating activities computed in accordance with
GAAP. “Adjusted EBITDA” is calculated by Kruger Products as net
income (loss) before (i) interest expense and other finance costs,
(ii) income taxes, (iii) depreciation, (iv) amortization, (v)
impairment (gain on sale) of non-financial assets, (vi) loss (gain)
on disposal of property, plant and equipment, (vii) foreign
exchange loss (gain), (viii) costs related to restructuring
activities, (ix) changes in amortized cost of Partnership units
liability, (x) change in fair value of derivatives, (xi) consulting
costs related to operational transformation initiatives, (xii)
corporate development related costs and (xiii) loss (gain) on sale
of shares. A reconciliation of Adjusted EBITDA to the relevant
reported results can be found in the Segment and Geographic Results
table of this news release.
Forward-Looking
StatementsCertain statements in this press release about
KPT’s and Kruger Products' current and future plans, expectations
and intentions, results, levels of activity, performance, goals or
achievements or any other future events or developments constitute
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements regarding
continued growth in the U.S. Consumer tissue business with the
White Cloud® brand and premium private label products, the expected
impact of our Sherbrooke Expansion Project, the expected start-up
dates of the facial tissue line and paper machine of the Sherbrooke
Expansion Project, expected growth and profitability in 2023 and
our expectation that Adjusted EBITDA1 in Q3 2023 will be in the
range of Q2 2023. The words "may", "will", "would", "should",
"could", "expects", "plans", "intends", "trends", "indications",
"anticipates", "believes", "estimates", "predicts", "likely" or
"potential" or the negative or other variations of these words or
other comparable words or phrases, are intended to identify
forward-looking statements. The forward-looking statements are
based on certain key expectations and assumptions made by KPT or
Kruger Products, including that inflationary pressure has
stabilized. Although KPT and Kruger Products believe that the
expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be
placed on the forward-looking statements since no assurance can be
given that such expectations and assumptions will prove to be
correct.
The outlook provided in respect of Adjusted
EBITDA1 for Q3 2023 and expected growth and profitability in 2023
is forward-looking information and is based on the assumptions and
subject to the risk and uncertainties referred to below. The
purpose of the outlook is to provide the reader with an indication
of management’s expectations, at the date of this press release,
regarding Kruger Products’ future financial performance. Readers
are cautioned that this information may not be appropriate for
other purposes.
Many factors could cause Kruger Products’ actual
results, level of activity, performance or achievements or future
events or developments (which could in turn affect the economic
benefits derived from KPT’s economic interest in Kruger Products),
to differ materially from those expressed or implied by the
forward-looking statements, including, without limitation, the
following factors, which are discussed in greater detail in the
“Risk Factors – Risks Related to Kruger Products’ Business” section
of the KPT Annual Information Form dated March 9, 2023 available on
SEDAR at www.sedar.com; Kruger Inc.’s influence over
Kruger Products; Kruger Products’ reliance on Kruger Inc.;
consequences of an event of insolvency relating to Kruger Inc.;
risks associated with the TAD Sherbrooke Project; risks associated
with the Sherbrooke Expansion Project; operational risks;
significant increases in input costs; reduction in supply of fibre;
increased pricing pressure and intense competition; Kruger
Products’ inability to innovate effectively; adverse economic
conditions; dependence on key retail trade customers; damage to the
reputation of Kruger Products or Kruger Products’ brands; Kruger
Products’ sales being less than anticipated; Kruger Products’
failure to implement its business and operating strategies; Kruger
Products’ obligation to make regular capital expenditures; Kruger
Products’ entering into unsuccessful acquisitions; Kruger Products’
dependence on key personnel; Kruger Products’ inability to retain
its existing customers or obtain new customers; Kruger Products’
loss of key suppliers; Kruger Products’ failure to adequately
protect its intellectual property rights; Kruger Products’ reliance
on third party intellectual property licenses; adverse litigation
and other claims affecting Kruger Products; material expenditures
due to comprehensive environmental regulation affecting Kruger
Products’ cash flow; Kruger Products’ pension obligations are
significant and can be materially higher than predicted if Kruger
Products Management’s underlying assumptions are incorrect; labour
disputes adversely affecting Kruger Products’ cost structure and
Kruger Products’ ability to run its plants; exchange rate and U.S.
competitors; Kruger Products’ inability to service all of its
indebtedness; exposure to potential consumer product liability;
covenant compliance; interest rate and refinancing risk; and risks
relating to information technology; cyber-security; insurance;
internal controls; trade; and risks related to COVID-19.
Readers should not place undue reliance on
forward-looking statements made herein. The forward-looking
information contained herein is expressly qualified in its entirety
by this cautionary statement. The forward-looking information
contained herein is made as of the date of press release and KPT
undertakes no obligation to publicly update such forward-looking
information to reflect new information, subsequent or otherwise,
unless required by applicable securities laws.
INFORMATION:
Francois ParoyanGeneral Counsel and Corporate SecretaryKP Tissue
Inc.Tel.: 905.812.6936francois.paroyan@krugerproducts.ca
INVESTORS:
Mike BaldesarraDirector of Investor RelationsKP Tissue Inc.Tel.:
905.812.6962IR@KPTissueinc.com
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements of Financial
Position |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
|
|
$ |
|
|
$ |
|
Assets |
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
88,245 |
|
|
71,261 |
|
|
Restricted cash |
9,702 |
|
|
7,145 |
|
|
Trade and other receivables |
118,777 |
|
|
119,681 |
|
|
Receivables from related parties |
245 |
|
|
223 |
|
|
Inventories |
262,509 |
|
|
286,566 |
|
|
Income tax recoverable |
4,119 |
|
|
1,306 |
|
|
Prepaid expenses |
14,301 |
|
|
5,640 |
|
|
|
497,898 |
|
|
491,822 |
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
1,321,358 |
|
|
1,294,838 |
|
|
Right-of-use assets |
78,066 |
|
|
81,715 |
|
|
Other long-term assets |
13,843 |
|
|
27,554 |
|
|
Pensions |
80,264 |
|
|
83,080 |
|
|
Goodwill |
152,021 |
|
|
152,021 |
|
|
Intangible assets |
28,374 |
|
|
30,027 |
|
|
Deferred income taxes |
29,375 |
|
|
95,711 |
|
Total assets |
2,201,199 |
|
|
2,256,768 |
|
|
|
|
|
|
Liabilities |
|
|
|
Current liabilities |
|
|
|
|
Trade and other payables |
277,667 |
|
|
279,425 |
|
|
Payables to related parties |
9,633 |
|
|
11,363 |
|
|
Dividends payable |
13,261 |
|
|
- |
|
|
Distributions payable |
- |
|
|
12,866 |
|
|
Current portion of long-term debt |
34,134 |
|
|
34,411 |
|
|
Current portion of lease liabilities |
28,313 |
|
|
28,349 |
|
|
Current portion of long-term payable to related party |
5,800 |
|
|
5,800 |
|
|
Current portion of provisions |
2,737 |
|
|
3,252 |
|
|
|
371,545 |
|
|
375,466 |
|
Non-current liabilities |
|
|
|
|
Long-term debt |
1,077,746 |
|
|
1,077,297 |
|
|
Long-term lease liabilities |
65,253 |
|
|
70,579 |
|
|
Long-term payable to related party |
34,460 |
|
|
39,042 |
|
|
Long-term provisions |
2,863 |
|
|
3,076 |
|
|
Pensions |
20,555 |
|
|
20,847 |
|
|
Post-retirement benefits |
46,244 |
|
|
43,739 |
|
|
Liabilities to non-equityholders |
1,618,666 |
|
|
1,630,046 |
|
|
Long-term portion of Partnership units liability |
- |
|
|
133,551 |
|
|
Total Partnership units liability |
- |
|
|
133,551 |
|
Total liabilities |
1,618,666 |
|
|
1,763,597 |
|
|
|
|
|
|
Equity |
|
|
|
|
Share capital |
650,469 |
|
|
- |
|
|
Partnership units |
- |
|
|
494,459 |
|
|
Deficit |
(158,661 |
) |
|
(87,835 |
) |
|
Accumulated other comprehensive income |
81,295 |
|
|
86,547 |
|
|
Equity attributable to Kruger Products |
573,103 |
|
|
493,171 |
|
|
Non-controlling interest |
9,430 |
|
|
- |
|
Total equity |
582,533 |
|
|
493,171 |
|
Total equity and liabilities |
2,201,199 |
|
|
2,256,768 |
|
|
|
|
|
|
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements of Income
(Loss) |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended June 30, 2023 |
|
3-month period ended June 30, 2022 |
|
6-month period ended June 30, 2023 |
|
6-month period ended June 30, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
Revenue |
466,302 |
|
|
397,499 |
|
|
917,294 |
|
|
796,238 |
|
|
|
|
|
|
|
|
|
Expenses |
|
|
|
|
|
|
|
Cost of sales |
395,712 |
|
|
372,489 |
|
|
784,736 |
|
|
736,344 |
|
Selling, general and administrative expenses |
40,640 |
|
|
35,111 |
|
|
76,901 |
|
|
63,966 |
|
Loss on sale of non-financial assets |
13 |
|
|
5 |
|
|
16 |
|
|
10 |
|
Restructuring costs, net |
84 |
|
|
352 |
|
|
1,223 |
|
|
868 |
|
|
|
|
|
|
|
|
|
Operating income (loss) |
29,853 |
|
|
(10,458 |
) |
|
54,418 |
|
|
(4,950 |
) |
|
|
|
|
|
|
|
|
Interest expense and other finance costs |
18,539 |
|
|
17,369 |
|
|
35,063 |
|
|
34,903 |
|
Other (income) expense |
(8,849 |
) |
|
12,599 |
|
|
(9,265 |
) |
|
8,284 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
20,163 |
|
|
(40,426 |
) |
|
28,620 |
|
|
(48,137 |
) |
|
|
|
|
|
|
|
|
Income tax expense (recovery) |
5,162 |
|
|
(4,913 |
) |
|
63,735 |
|
|
(14,061 |
) |
|
|
|
|
|
|
|
|
Net income (loss) including non-controlling
interest |
15,001 |
|
|
(35,513 |
) |
|
(35,115 |
) |
|
(34,076 |
) |
|
|
|
|
|
|
|
|
Net income (loss) attributable to non-controlling
interest |
517 |
|
|
- |
|
|
(338 |
) |
|
- |
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Kruger
Products |
14,484 |
|
|
(35,513 |
) |
|
(34,777 |
) |
|
(34,076 |
) |
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements of
Comprehensive Income (Loss) |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended June 30, 2023 |
|
3-month period ended June 30, 2022 |
|
6-month period ended June 30, 2023 |
|
6-month period ended June 30, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
Net income (loss) including non-controlling
interest |
15,001 |
|
|
(35,513 |
) |
|
(35,115 |
) |
|
(34,076 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
Items that will not be reclassified to net income
(loss): |
|
|
|
|
|
|
|
Remeasurements of pensions |
(4,037 |
) |
|
89,304 |
|
|
(19,881 |
) |
|
194,925 |
|
Remeasurements of post-retirement benefits |
(452 |
) |
|
6,190 |
|
|
10,190 |
|
|
14,051 |
|
Items that may be subsequently reclassified to
net income (loss): |
|
|
|
|
|
|
|
|
Cumulative translation adjustment |
(5,040 |
) |
|
8,422 |
|
|
(5,252 |
) |
|
4,385 |
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
(9,529 |
) |
|
103,916 |
|
|
(14,943 |
) |
|
213,361 |
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss) including
non-controlling interest |
5,472 |
|
|
68,403 |
|
|
(50,058 |
) |
|
179,285 |
|
Total comprehensive income (loss) attributable to
non-controlling interest |
517 |
|
|
- |
|
|
(338 |
) |
|
- |
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss) attriutable to
Kruger Products |
4,955 |
|
|
68,403 |
|
|
(49,720 |
) |
|
179,285 |
|
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements of Cash
Flows |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended June 30, 2023 |
|
3-month period ended June 30, 2022 |
|
6-month period ended June 30, 2023 |
|
6-month period ended June 30, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
Cash flows from (used in) operating
activities |
|
|
|
|
|
|
|
Net income (loss) including non-controlling interest |
15,001 |
|
|
(35,513 |
) |
|
(35,115 |
) |
|
(34,076 |
) |
Items not affecting cash |
|
|
|
|
|
|
|
Depreciation |
22,889 |
|
|
20,778 |
|
|
46,078 |
|
|
42,760 |
|
Amortization |
1,096 |
|
|
1,125 |
|
|
2,161 |
|
|
2,169 |
|
Loss on sale of property, plant and equipment |
1,114 |
|
|
18 |
|
|
1,109 |
|
|
18 |
|
Gain on disposal of leased assets |
- |
|
|
- |
|
|
(488 |
) |
|
- |
|
Foreign exchange (gain) loss |
(8,849 |
) |
|
12,599 |
|
|
(9,265 |
) |
|
8,284 |
|
Interest expense and other finance costs |
18,539 |
|
|
17,369 |
|
|
35,063 |
|
|
34,903 |
|
Pension and post-retirement benefits |
2,224 |
|
|
3,576 |
|
|
4,112 |
|
|
7,270 |
|
Provisions |
508 |
|
|
733 |
|
|
1,939 |
|
|
494 |
|
Income tax expense (recovery) |
5,162 |
|
|
(4,913 |
) |
|
63,735 |
|
|
(14,061 |
) |
Loss on sale of non-financial assets |
13 |
|
|
5 |
|
|
16 |
|
|
10 |
|
Total items not affecting cash |
42,696 |
|
|
51,290 |
|
|
144,460 |
|
|
81,847 |
|
|
|
|
|
|
|
|
|
Net change in non-cash working capital |
68,307 |
|
|
(20,031 |
) |
|
16,858 |
|
|
(66,521 |
) |
Contributions to pension and post-retirement benefit plans |
(2,680 |
) |
|
(4,157 |
) |
|
(5,198 |
) |
|
(8,340 |
) |
Provisions paid |
(2,585 |
) |
|
(3,733 |
) |
|
(3,274 |
) |
|
(3,915 |
) |
Income tax payments, net |
(1,621 |
) |
|
(1,168 |
) |
|
(1,458 |
) |
|
(1,488 |
) |
Net cash from (used in) operating activities |
119,118 |
|
|
(13,312 |
) |
|
116,273 |
|
|
(32,493 |
) |
|
|
|
|
|
|
|
|
Cash flows from (used in) investing
activities |
|
|
|
|
|
|
|
Purchases of property, plant and equipment |
(4,669 |
) |
|
(18,431 |
) |
|
(8,680 |
) |
|
(18,930 |
) |
Purchases of property, plant and equipment and software
related to the TAD Sherbrooke Project |
(743 |
) |
|
(5,598 |
) |
|
(743 |
) |
|
(10,929 |
) |
Purchases of property, plant and equipment related to the
Sherbrooke Expansion Project |
(36,798 |
) |
|
(14,704 |
) |
|
(68,460 |
) |
|
(20,748 |
) |
Interest paid on credit facilities related to the Sherbrooke
Expansion Project |
(119 |
) |
|
(306 |
) |
|
(216 |
) |
|
(306 |
) |
Government assistance received |
- |
|
|
- |
|
|
1,250 |
|
|
- |
|
Purchases of software |
(437 |
) |
|
(304 |
) |
|
(508 |
) |
|
(4,759 |
) |
Proceeds on sale of property, plant and equipment |
2,443 |
|
|
1 |
|
|
2,448 |
|
|
1 |
|
Net cash used in investing activities |
(40,323 |
) |
|
(39,342 |
) |
|
(74,909 |
) |
|
(55,671 |
) |
|
|
|
|
|
|
|
|
Cash flows from (used in) financing
activities |
|
|
|
|
|
|
|
Proceeds from long-term debt |
21,281 |
|
|
75,550 |
|
|
56,782 |
|
|
217,506 |
|
Repayment of long-term debt |
(14,874 |
) |
|
(6,907 |
) |
|
(23,569 |
) |
|
(125,446 |
) |
Payment of deferred financing fees |
(134 |
) |
|
823 |
|
|
(380 |
) |
|
(1,312 |
) |
Payment of lease liabilities |
(7,046 |
) |
|
(7,426 |
) |
|
(13,796 |
) |
|
(14,411 |
) |
Change in Restricted cash |
(1,332 |
) |
|
(1,166 |
) |
|
(2,557 |
) |
|
(2,312 |
) |
Interest paid on long-term debt |
(17,641 |
) |
|
(16,094 |
) |
|
(31,360 |
) |
|
(24,987 |
) |
Payment to related party |
(5,700 |
) |
|
- |
|
|
(5,700 |
) |
|
- |
|
Dividends paid, net |
(1,761 |
) |
|
- |
|
|
(3,504 |
) |
|
- |
|
Distributions and advances paid, net |
- |
|
|
(7,046 |
) |
|
- |
|
|
(14,021 |
) |
Net cash from (used in) financing activities |
(27,207 |
) |
|
37,734 |
|
|
(24,084 |
) |
|
35,017 |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and
cash |
|
|
|
|
|
|
|
equivalents held in foreign currency |
(259 |
) |
|
426 |
|
|
(296 |
) |
|
160 |
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents
during the period |
51,329 |
|
|
(14,494 |
) |
|
16,984 |
|
|
(52,987 |
) |
|
|
|
|
|
|
|
|
Cash and cash equivalents - Beginning of
period |
36,916 |
|
|
110,026 |
|
|
71,261 |
|
|
148,519 |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - End of period |
88,245 |
|
|
95,532 |
|
|
88,245 |
|
|
95,532 |
|
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Segment and Geographic Results |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended June 30, 2023 |
|
3-month period ended June 30, 2022 |
|
6-month period ended June 30, 2023 |
|
6-month period ended June 30, 2022 |
|
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
|
Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Revenue |
|
|
|
|
|
|
|
|
Consumer |
|
383,477 |
|
|
326,333 |
|
|
759,997 |
|
|
669,175 |
|
AFH |
|
82,825 |
|
|
71,166 |
|
|
157,297 |
|
|
127,063 |
|
|
|
|
|
|
|
|
|
|
Total segment revenue |
|
466,302 |
|
|
397,499 |
|
|
917,294 |
|
|
796,238 |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
|
|
|
|
|
|
|
Consumer |
|
53,308 |
|
|
14,298 |
|
|
104,642 |
|
|
49,681 |
|
AFH |
|
5,834 |
|
|
(451 |
) |
|
6,718 |
|
|
(3,672 |
) |
Corporate and other costs |
|
(4,093 |
) |
|
(2,027 |
) |
|
(6,355 |
) |
|
(5,134 |
) |
|
|
|
|
|
|
|
|
|
Total Adjusted EBITDA |
|
55,049 |
|
|
11,820 |
|
|
105,005 |
|
|
40,875 |
|
|
|
|
|
|
|
|
|
|
Reconciliation to net income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
23,985 |
|
|
21,903 |
|
|
48,239 |
|
|
44,929 |
|
Interest expense and other finance costs |
|
18,539 |
|
|
17,369 |
|
|
35,063 |
|
|
34,903 |
|
Loss on sale of property, plant and equipment |
|
1,114 |
|
|
18 |
|
|
1,109 |
|
|
18 |
|
Loss on sale of non-financial assets |
|
13 |
|
|
5 |
|
|
16 |
|
|
10 |
|
Restructuring costs, net |
|
84 |
|
|
352 |
|
|
1,223 |
|
|
868 |
|
Foreign exchange (gain) loss |
|
(8,849 |
) |
|
12,599 |
|
|
(9,265 |
) |
|
8,284 |
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
20,163 |
|
|
(40,426 |
) |
|
28,620 |
|
|
(48,137 |
) |
|
|
|
|
|
|
|
|
|
Income tax recovery |
|
5,162 |
|
|
(4,913 |
) |
|
63,735 |
|
|
(14,061 |
) |
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
15,001 |
|
|
(35,513 |
) |
|
(35,115 |
) |
|
(34,076 |
) |
|
|
|
|
|
|
|
|
|
Geographic Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Canada |
|
265,165 |
|
|
239,286 |
|
|
525,945 |
|
|
482,206 |
|
US |
|
201,137 |
|
|
158,213 |
|
|
391,349 |
|
|
314,032 |
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
466,302 |
|
|
397,499 |
|
|
917,294 |
|
|
796,238 |
|
|
|
|
|
|
|
|
|
|
KP Tissue Inc. |
Unaudited Condensed Statements of Financial
Position |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
|
$ |
|
|
$ |
|
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
|
Dividends receivable |
1,791 |
|
|
- |
|
Distributions receivable |
- |
|
|
1,790 |
|
Income tax recoverable |
580 |
|
|
580 |
|
|
2,371 |
|
|
2,370 |
|
|
|
|
|
Non-current assets |
|
|
|
Investment in associate |
68,785 |
|
|
79,338 |
|
|
|
|
|
Total assets |
71,156 |
|
|
81,708 |
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
Dividend payable |
1,791 |
|
|
1,790 |
|
Payable to investee |
170 |
|
|
- |
|
Payable to Partnership |
- |
|
|
170 |
|
|
1,961 |
|
|
1,960 |
|
Non-current liabilities |
|
|
|
Deferred income taxes |
- |
|
|
5,718 |
|
|
|
|
|
Total liabilities |
1,961 |
|
|
7,678 |
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
Common shares |
22,458 |
|
|
22,379 |
|
Contributed surplus |
144,819 |
|
|
144,819 |
|
Deficit |
(114,188 |
) |
|
(108,008 |
) |
Accumulated other comprehensive income |
16,106 |
|
|
14,840 |
|
|
|
|
|
Total equity |
69,195 |
|
|
74,030 |
|
|
|
|
|
Total liabilities and equity |
71,156 |
|
|
81,708 |
|
|
|
|
|
KP Tissue Inc. |
Unaudited Condensed Statements of Income (Loss) and
Comprehensive Income (Loss) |
(thousands of Canadian dollars, except share and per share
amounts) |
|
|
|
|
|
|
|
|
|
3-month period ended June 30, 2023 |
|
3-month period ended June 30, 2022 |
|
6-month period ended June 30, 2023 |
|
6-month period ended June 30, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
Equity income (loss) |
1,761 |
|
|
(6,423 |
) |
|
(5,298 |
) |
|
(7,531 |
) |
Dilution gain |
252 |
|
|
127 |
|
|
525 |
|
|
200 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
2,013 |
|
|
(6,296 |
) |
|
(4,773 |
) |
|
(7,331 |
) |
|
|
|
|
|
|
|
|
Income tax expense (recovery) |
- |
|
|
(2,348 |
) |
|
3,892 |
|
|
(4,361 |
) |
|
|
|
|
|
|
|
|
Net income (loss) |
2,013 |
|
|
(3,948 |
) |
|
(8,665 |
) |
|
(2,970 |
) |
|
|
|
|
|
|
|
|
Other comprehensive income
(loss) |
|
|
|
|
|
|
|
net of tax expense
(recovery) |
|
|
|
|
|
|
|
Items that will not be reclassified to
net income (loss): |
|
|
|
|
|
|
|
Remeasurements of pensions |
(514 |
) |
|
7,884 |
|
|
4,209 |
|
|
18,132 |
|
Remeasurements of post-retirement benefits |
(82 |
) |
|
729 |
|
|
1,859 |
|
|
1,399 |
|
Items that may be subsequently reclassified
to net income (loss): |
|
|
|
|
|
|
|
|
Cumulative translation adjustment |
(817 |
) |
|
1,186 |
|
|
1,266 |
|
|
591 |
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
(1,413 |
) |
|
9,799 |
|
|
7,334 |
|
|
20,122 |
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss) |
600 |
|
|
5,851 |
|
|
(1,331 |
) |
|
17,152 |
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share |
0.20 |
|
|
(0.40 |
) |
|
(0.87 |
) |
|
(0.30 |
) |
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
9,953,131 |
|
|
9,935,108 |
|
|
9,951,513 |
|
|
9,930,492 |
|
|
|
|
|
|
|
|
|
KP Tissue Inc. |
Unaudited Condensed Statements of Cash Flows |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
3-month period ended June 30, 2023 |
|
3-month period ended June 30, 2022 |
|
6-month period ended June 30, 2023 |
|
6-month period ended June 30, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
Cash flows from (used in) operating
activities |
|
|
|
|
|
|
|
Net income (loss) |
2,013 |
|
|
(3,948 |
) |
|
(8,665 |
) |
|
(2,970 |
) |
Items not affecting cash |
|
|
|
|
|
|
|
Equity loss (income) |
(1,761 |
) |
|
6,423 |
|
|
5,298 |
|
|
7,531 |
|
Dilution gain |
(252 |
) |
|
(127 |
) |
|
(525 |
) |
|
(200 |
) |
Income tax expense (recovery) |
- |
|
|
(2,348 |
) |
|
3,892 |
|
|
(4,361 |
) |
Total items not affecting cash |
(2,013 |
) |
|
3,948 |
|
|
8,665 |
|
|
2,970 |
|
|
|
|
|
|
|
|
|
Net change in non-cash working capital |
- |
|
|
(169 |
) |
|
- |
|
|
(169 |
) |
Tax payments, net |
- |
|
|
169 |
|
|
- |
|
|
131 |
|
Tax Distribution received, net |
- |
|
|
- |
|
|
- |
|
|
38 |
|
|
|
|
|
|
|
|
|
Net cash from (used in) operating activities |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
Dividends received |
1,761 |
|
|
- |
|
|
3,503 |
|
|
- |
|
Partnership unit distributions received |
- |
|
|
1,741 |
|
|
- |
|
|
3,144 |
|
|
|
|
|
|
|
|
|
Net cash from investing activities |
1,761 |
|
|
1,741 |
|
|
3,503 |
|
|
3,144 |
|
|
|
|
|
|
|
|
|
Cash flows used in financing activities |
|
|
|
|
|
|
|
Dividends paid, net |
(1,761 |
) |
|
(1,741 |
) |
|
(3,503 |
) |
|
(3,144 |
) |
|
|
|
|
|
|
|
|
Net cash used in financing activities |
(1,761 |
) |
|
(1,741 |
) |
|
(3,503 |
) |
|
(3,144 |
) |
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents
during the period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - Beginning of
period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - End of period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
KP Tissue (TSX:KPT)
過去 株価チャート
から 11 2024 まで 12 2024
KP Tissue (TSX:KPT)
過去 株価チャート
から 12 2023 まで 12 2024